Swindon's Great Western Hospital is one of five trust offering a new treatment for sleep apnoea.

Resmed remains the best performer of biotech's Big Four, but some investors aren't sleeping tight after last week's $700 ...

The FDA's acceptance of the NDA for AD109 marks a pivotal clinical milestone toward introducing the first oral pharmacotherapy designed to target the neuromuscular causes of obstructive sleep apnea.

Cambridge biotech Apnimed has filed for an initial public offering as it awaits Food and Drug Administration approval for its ...

Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, ...

Some companies are shifting towards influencer-style videos – but with regular customers and employees, not cultivated internet personalities.

At some point, you’ve probably had to wake up in the night to pee. Pregnancy, drinking too much water before bed or certain ...

Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering ​in the U.S. on Friday.

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized.

A team of researchers from the University of Auckland is studying a promising new medicine that may one day help people living with both heart failure and sleep apnea. Although the treatment is still ...

Vitality Medical reports that Hawai‘i faces the largest gap between sleep therapy needs and access, with 45.4% of residents ...

A single night of sleep testing may not be enough to diagnose sleep apnea, with new Flinders University research revealing ...